DeBinge Clinical Education

Alcohol Detox Is Only the Beginning: How Long-Acting Naltrexone May Support Recovery After Withdrawal

Prepared for medical review.
Review status: Pending.

For many people with alcohol dependence, the hardest question is not simply, How do I stop drinking? It is: How do I stop, get through withdrawal safely, and then avoid being pulled back into the same cycle weeks or months later?

That distinction matters. Alcohol withdrawal can be medically serious, and detoxification addresses the immediate problem of stopping alcohol safely. But detox is only the beginning of treatment for alcohol use disorder. The longer challenge is what happens after alcohol has left the body: cravings, familiar triggers, learned habits, stress, social situations and the rewarding effect a person has learned to associate with drinking.

This is where naltrexone can play an important role. Naltrexone does not sedate a person or create an alcohol-disulfiram reaction. Instead, it blocks opioid receptors involved in some of alcohol’s rewarding effects. In suitable patients, this can reduce craving and heavy drinking and may make alcohol-related cues less compelling.

Detox solves one problem. Recovery has to solve the next one.

For someone who is physically dependent on alcohol, suddenly stopping can cause tremor, sweating, anxiety, insomnia and agitation. In more serious cases, withdrawal can include seizures or delirium. For that reason, people at meaningful withdrawal risk should be medically assessed rather than attempting abrupt detoxification alone.

In medically supervised withdrawal, benzodiazepines such as diazepam (Valium) are commonly used when clinically appropriate. Their role is to control withdrawal symptoms and reduce the risk of serious complications. The dose and monitoring plan should be individualized according to withdrawal severity, previous withdrawal history, liver function, other medications and the patient’s broader medical condition.

However, completing detox does not mean alcohol use disorder has been treated. A person may leave withdrawal feeling physically stable and still encounter the same cues that previously led to drinking: Friday evening, stress after work, an argument, seeing a bottle, meeting certain friends, passing a familiar bar, loneliness or the expectation that alcohol will provide relief.

What naltrexone changes is not necessarily whether alcohol enters your thoughts

A useful way to understand naltrexone is to separate a thought from an instruction.

Before treatment, an alcohol-related thought can sometimes feel urgent: “I want a drink. I need one.”

With effective treatment, some people may experience something more like: “I am thinking about alcohol, but I do not have to act on that thought.”

This is not a guaranteed experience, and naltrexone does not erase every craving. But research supports the underlying mechanism. Naltrexone is used in alcohol use disorder because it can reduce alcohol’s rewarding effects and, in some people, reduce craving and heavy drinking. Brain-imaging research with extended-release naltrexone has also shown reduced responses to alcohol-related cues in regions involved in reward, emotion, learning and decision-making.

In practical terms, the goal is not to make a person never think about alcohol again. It is to help create more space between thought and action.

Why continuity may matter more than convenience

Long-acting treatment is often described as convenient. That understates its potential importance in addiction treatment.

Oral naltrexone only works on the days it is taken. A person taking tablets must keep making the decision to continue treatment. Unfortunately, the day somebody is most tempted to drink may also be the day they decide to skip the medication.

Monthly extended-release naltrexone reduces that daily adherence burden, but still requires repeated treatment appointments. Research published in 2026 found higher treatment persistence with extended-release naltrexone than with oral naltrexone in people with alcohol use disorder. That does not prove that an implant is superior, but it supports an important principle: formulation can influence whether treatment actually remains in place over time.

A long-acting implant is designed to take repeated medication decisions out of the day-to-day recovery process. The medication decision is made at a planned moment, rather than being reopened during every difficult evening, stressful week or craving episode.

The value of long-acting treatment may not be what happens on the easiest day of recovery. Its value may be that treatment is still there on the hardest day.

Continuity may give triggers time to lose some of their authority

Alcohol addiction is strongly connected with learned cues. Repeated drinking can train the brain to connect alcohol with certain people, places, emotions and routines. Those cues can later provoke powerful urges even after someone has decided to stop.

Research using functional brain imaging suggests that extended-release naltrexone can attenuate the salience of alcohol-related cues. In other words, a trigger may still be noticed, but it may not produce the same degree of motivational pull.

This distinction is important. A trigger does not have to disappear to become less powerful.

Over months of recovery, a person may repeatedly experience situations that previously ended in drinking:

stress does not have to end in alcohol;
Friday night does not have to mean getting drunk;
an argument does not have to be followed by a drink;
a restaurant does not have to mean ordering alcohol;
seeing alcohol does not have to mean consuming it.

That repeated experience matters because recovery is not only about resisting one craving. It is about building a different pattern of response over time.

Why sustained pharmacological support can complement counselling

Counselling asks a person to do difficult work: identify triggers, recognize automatic thoughts, practise coping strategies, repair relationships, change routines and learn how to live through stress without returning to alcohol.

Naltrexone cannot do those things for the patient. What it may do is change the conditions in which that psychological work takes place.

If alcohol feels less rewarding, if certain cues produce less urgency and if medication remains present through difficult periods, counselling may have more uninterrupted time to help the patient develop new responses.

The important word is time. Recovery skills do not become automatic after one session. New habits need repetition. Confidence needs experiences of succeeding in real situations. Relationships need time to repair. A person may need months of ordinary life to discover that a trigger they once considered irresistible is something they can now experience without drinking.

This is why continuity can be more than medication adherence. It can help create a period in which recovery itself has time to accumulate.

A treatment a patient may barely feel, but may notice in everyday life

Naltrexone is not intended to make a person feel intoxicated, euphoric or sedated. Many patients do not experience a dramatic subjective “drug effect.” That can make the treatment feel relatively invisible compared with medications whose effects are immediately noticeable.

The difference may instead appear in everyday decisions: getting through a stressful evening without drinking, walking past a familiar bar without the same urgency, noticing that a craving passes, or realizing that an alcohol-related thought no longer automatically determines what happens next.

That does not mean naltrexone has no side effects. Nausea, headache, dizziness, fatigue or other adverse effects can occur, and suitability should be assessed medically. The point is that the intended therapeutic effect is not a new sensation—it is a change in alcohol-related reward and behaviour.

Daily tablet, monthly injection or long-acting implant?

In the United States, oral naltrexone and extended-release injectable naltrexone are established treatment options for alcohol use disorder. The practical differences are largely about delivery and adherence.

Form	Typical treatment pattern	Practical consideration
Oral naltrexone	Usually taken daily	Requires ongoing day-to-day adherence
Extended-release injectable naltrexone	Usually administered monthly	Reduces daily dosing decisions but requires repeat injections
Long-acting implant	Designed for sustained release over months, depending on formulation	May substantially reduce repeated medication decisions, but evidence for implants in AUD is more limited

A longer-lasting formulation should not automatically be described as a stronger medication. The molecule is still naltrexone. The proposed advantage is continuity of delivery.

What is the FDA status?

This distinction is essential for U.S. readers.

Oral naltrexone and extended-release injectable naltrexone have FDA-approved formulations for alcohol dependence/alcohol use disorder.

Long-acting naltrexone implants are not FDA-approved in the United States for alcohol use disorder. Research into sustained-release and implantable naltrexone continues, but the evidence base specifically for implants in alcohol use disorder is substantially smaller than the evidence for oral and monthly injectable naltrexone.

That means an implant should not be presented as a proven superior replacement for established U.S. medications. It is better understood as a different long-acting delivery strategy whose potential value includes sustained exposure and reduced adherence burden.

How the DeBinge pathway differs from conventional group rehab

One important difference is what happens at the point a patient is ready to leave detox. In the United States, hospitals and detox units may discharge a patient once the dangerous withdrawal phase has passed and the person is medically stable, with ongoing addiction treatment arranged at a lower level of care. Some U.S. programs also begin FDA-approved alcohol-use-disorder medications such as oral or monthly injectable naltrexone before or after discharge, so it would be inaccurate to suggest that every U.S. patient leaves detox without relapse-prevention treatment.

The DeBinge pathway is designed around a different transition: for a suitable patient, the goal is that medically managed withdrawal is followed by long-acting naltrexone before the patient leaves The Bahamas, with counselling continuing after they return home. The patient therefore does not simply finish withdrawal and then have to decide later whether to begin relapse-prevention treatment; the pharmacological support and the longer recovery plan are intended to be in place before departure.

This distinction matters because the period after withdrawal can still include cravings, familiar triggers, stress and learned drinking cues. Naltrexone does not make relapse impossible, but it can reduce alcohol craving and reward in some people. A long-acting formulation may also reduce repeated medication decisions, giving counselling and new behavioural patterns more uninterrupted time to develop.

DeBinge is located in Nassau, The Bahamas. It does not operate a treatment facility in the United States.

The DeBinge model is designed as a private, individualized and concierge-style treatment pathway rather than a conventional group-based residential rehabilitation program. Subject to medical assessment, the pathway may include medically managed alcohol withdrawal, long-acting naltrexone treatment, private clinical care and one year of counselling and recovery support.

The aim is not to suggest that medication replaces counselling or that an implant makes relapse impossible. The goal is to combine pharmacological continuity with psychological recovery work over a much longer period than the initial detox episode.

For a privately paying patient, that creates a different question from simply comparing the price of one medication with another:

What does the patient receive over the full course of recovery—and how long does that support continue?

Recovery is not simply removing alcohol from the body

Detox can be an essential first step. But the deeper goal is not simply to reach the first alcohol-free day. It is to reach a point where alcohol no longer dictates what happens next.

Naltrexone may help by reducing alcohol reward, craving or cue salience in some people. Long-acting delivery may help by keeping treatment present without requiring repeated medication decisions. Counselling can then work on the parts medication cannot: behaviour, relationships, triggers, coping, identity and rebuilding daily life.

Over time, the hoped-for progression is not:

Trigger → craving → drinking.

It becomes:

Trigger → thought → pause → choice → a different action.

That is why continuity matters. It gives recovery the opportunity to become something a person repeatedly lives, rather than something they repeatedly have to restart.

Deeper guides on alcohol recovery after detox

Medical review

Prepared for medical review — Review status: Pending.

Medical reviewer: Dr Fergus Law, BSc, MBChB, FRCPsych, Consultant Psychiatrist specialising in substance misuse and addiction.

This article is for general educational information and does not provide individual medical advice. Alcohol withdrawal can be dangerous. People who may be physically dependent on alcohol should seek professional medical assessment before abruptly stopping drinking. Naltrexone is not suitable for everyone, particularly people currently using opioids or with certain medical conditions. Treatment suitability and regulatory status vary by jurisdiction.

Selected evidence

Considering a private alcohol-treatment consultation? Request a confidential consultation with DeBinge.